Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
SUBSTITUTED TRIAZINE COMPOUND
Document Type and Number:
WIPO Patent Application WO/2022/230912
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The present inventors have conducted an intensive examination to search for a compound having an NLRP3 inflammasome activation inhibiting action, and have found that a substituted triazine compound has an NLRP3 inflammasome activation inhibiting action, thereby completing the present invention. A substituted triazine compound according to the present invention is expected to serve as a drug for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases.

Inventors:
INAGAKI YUSUKE (JP)
YAMASHITA YUMI (JP)
TOYA HIROKI (JP)
WASHIO TAKUYA (JP)
TAKAHASHI FUMIE (JP)
SABA KENGO (JP)
TOMIYAMA HIROSHI (JP)
IWAI YOSHINORI (JP)
NAKAMURA AKIHIKO (JP)
Application Number:
PCT/JP2022/018994
Publication Date:
November 03, 2022
Filing Date:
April 27, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ASTELLAS PHARMA INC (JP)
KOTOBUKI PHARMACEUTICAL CO LTD (JP)
International Classes:
C07D253/07; A61K31/53; A61K31/5377; A61K31/55; A61P25/00; A61P29/00; A61P43/00; C07D401/12; C07D401/14; C07D403/12; C07D405/12; C07D405/14; C07D409/12; C07D413/12
Domestic Patent References:
WO2020163248A12020-08-13
WO2019191229A12019-10-03
WO2021193897A12021-09-30
WO2020234715A12020-11-26
WO2019008025A12019-01-10
WO2017184604A12017-10-26
WO2018015445A12018-01-25
WO2021193897A12021-09-30
WO2019191229A12019-10-03
WO2020163248A12020-08-13
WO2011133920A12011-10-27
Foreign References:
US20200361898A12020-11-19
Other References:
KHOSHNEVISZADEH MEHDI; GHAHREMANI MOHAMMAD H.; FOROUMADI ALIREZA; MIRI RAMIN; FIRUZI OMIDREZA; MADADKAR-SOBHANI ARMIN; EDRAKI NAJM: "Design, synthesis and biological evaluation of novel anti-cytokine 1,2,4-triazine derivatives", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 21, 13 August 2013 (2013-08-13), AMSTERDAM, NL, pages 6708 - 6717, XP028732714, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2013.08.009
NATURE GENETICS, vol. 29, no. 3, 2001, pages 301 - 305
ARTHRITIS RESEARCH AND THERAPY, vol. 12, no. 2, 2010
JOURNAL OF MOLECULAR MEDICINE, vol. 92, no. 10, 2014, pages 1069 - 1082
GUT, vol. 59, no. 9, 2010, pages 1192 - 1100
NATURE, vol. 493, no. 7434, 2013, pages 674 - 678
PLOS ONE, vol. 8, no. 1, 2013
INFLAMMATION, vol. 41, no. 1, 2018, pages 93 - 103
JOURNAL OF NEUROPATHOLOGY AND EXPRIMENTAL NEUROLOGY, vol. 77, no. 11, 2018, pages 1055 - 1065
SCIENCE TRANSLATIONAL MEDICINE, vol. 10, no. eaah4066, 2018
PROG. MED., vol. 5, 1985, pages 2157 - 2161
HIROKAWA SHOTEN: "Development of pharmaceuticals", MOLECULAR DESIGN, vol. 7, 1990, pages 163 - 198
P. G. M. WUTST. W. GREENE: "Greene's Protective Groups in Organic Synthesis", 2006
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 127, 2005, pages 4685 - 4696
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, vol. 12, no. 1, 2009, pages 78 - 95
Attorney, Agent or Firm:
YAMAMOTO, Osamu et al. (JP)
Download PDF: